

Hikma acquires the rights to a portfolio of Takeda brands for the MENA region

London, 19 December 2024 – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today announces that it has agreed with Takeda Pharmaceuticals International AG (Takeda) to acquire the rights to 17 brands currently licensed to Hikma for select territories in the Middle East and North Africa (MENA) region.

Through a number of licensing contracts, the latest of which was entered into in 2017, Hikma developed a strategic partnership with Takeda to license, commercialise and, in some cases, manufacture a portfolio of products in the MENA region. Today the portfolio includes attractive and growing branded products used for cardiovascular, diabetes, gastroenterology and pain management.

Hikma has now agreed with Takeda that it will acquire the rights to these marketed brands. Hikma will continue to commercialise all 17 brands and will, over time, move the manufacture of these products in-house. This will ensure the continuity of supply of these important medicines, which are widely used by patients across the region. The acquisition will result in improved efficiency and cost saving opportunities, which will support the profitability of the Branded business.

Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA said: *"We have been successfully commercialising this portfolio of products across the region for a number of years, supported by our highly-specialised sales and marketing team with strong local market expertise. By bringing these products in-house, we will not only ensure an uninterrupted supply of products to our customers but will also have better control of our supply chain, which will result in cost saving opportunities over the medium term. We are confident this acquisition will strengthen our Branded business and reinforce our commitment to provide high-quality medicines to patients in MENA."*

The acquisition is subject to customary legal and regulatory closing conditions.

-- ENDS --

Enquiries:

Hikma (Investors)

Susan Ringdal +44 (0)20 7399 2760/ +44 (0)7776 477050
EVP, Strategic Planning and Global Affairs

Guy Featherstone +44 (0)20 3892 4389/ +44 (0)7795 896738
Director, Investor Relations

Layan Kalisse +44 (0)20 7399 2788/ +44 (0)7970 709912
Senior Associate, Investor Relations

Press

Teneo - Rob Yates +44 (0)7715 375443

Hikma – Mona Abdallah + 962 6 5802900
Senior Director, MENA Communications



About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

©2024 Hikma Pharmaceuticals PLC. All rights reserved.